Showing results (81-90 of 202) with videos related to

Sort By:
Pageof 21
Journal of Acquired Immune Deficiency Syndromes (1999)|August 13, 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2W David Hardy, Roy M Gulick, Howard Mayer, et al.
The Journal of Infectious Diseases|October 2, 2002
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionAndrew N Phillips, Schlomo Staszewski, Fiona Lampe, et al.
The Journal of Infectious Diseases|March 20, 2004
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359Courtney V Fletcher, Hongyu Jiang, Richard C Brundage, et al.
Antiviral Therapy|February 22, 2007
Design issues in initial HIV-treatment trials: focus on ACTG A5095Heather J Ribaudo, Daniel R Kuritzkes, Bruce R Schackman, et al.
The Journal of Infectious Diseases|November 4, 2005
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks, Lydia M Petrovic, Andrew H Talal, et al.
AIDS (London, England)|June 27, 2008
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)Brigitte Autran, Robert L Murphy, Dominique Costagliola, et al.
JAMA|July 14, 2004
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJoel E Gallant, Schlomo Staszewski, Anton L Pozniak, et al.
HIV Medicine|March 14, 2007
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2, Zoe Fox, Francisco Antunes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 4, 2010
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095Jeffrey T Schouten, Amy Krambrink, Heather J Ribaudo, et al.
AIDS Care|April 12, 2024
Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidatesJeremy Sugarman, Brian W Weir, Chen Dun, et al.
Pageof 21